A Study of AVZO-103 Alone or in Combination With Pembrolizumab in People With Solid Tumor Cancer

Full Title

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients with Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Gopa Iyer’s office at 646-888-4737.